Cynapsus Therapeutics Provides European Clinical Update for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cynapsus Therapeutics Provides European Clinical Update for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease

-- Company plans to initiate pivotal program in fourth quarter -- -- Webcast with accompanying slides to discuss program tomorrow at 7:30 a.m. Eastern time --

TORONTO, July 18, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ: CYNA ) (TSX: CTH ), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD), today provided an update on its European clinical plan following meetings with regulatory authorities.  Agreement with the EMA has been reached on the design, duration and size for the clinical studies as well as the endpoints.  Based on this, Cynapsus plans to initiate a pivotal clinical program evaluating the safety and efficacy of APL-130277 in PD patients in the fourth quarter of 2016.

Current European Clinical Trial Plan:

  • Expect to conduct an active comparator study with sub-cutaneous apomorphine
  • Up to 80 patients will be randomized in a 4-week open label crossover study
  • Functional endpoints will be assessed and will include the duration of ON, preference and ease-of-use of APL-130277, the use of patient diaries, and tolerability of APL-130277
  • The use of an anti-emetic should be limited during the study
  • Based on current trial timing, the European clinical trial is expected to commence in the fourth quarter of 2016

“We are pleased with the outcome of our meeting with the European regulatory authorities and appreciate the collaborative process that led to the agreed upon design of the study,” said Anthony Giovinazzo, President and CEO of Cynapsus. “We better understand the EMA’s guidance on the safety and efficacy requirements for the clinical study for the use of APL-130277 in patients with PD.  Furthermore, we are pleased that the design takes into account that the effect of apomorphine is well-established and the benefit of a sublingual application is apparent. We look forward to continuing to work closely with the European regulatory authorities to complete this study.”

About Parkinson’s Disease and OFF Episodes

The European Parkinson's disease Association estimates that 1.2 million people have PD in the European Union.  More than 1 million people in the U.S. and an estimated 4 to 6 million people worldwide suffer from PD. It is a chronic, progressive neurodegenerative disease characterized by motor symptoms, including tremor at rest, rigidity and impaired movement, as well as significant non-motor symptoms, including cognitive impairment and mood disorders. PD’s prevalence is increasing with the aging of the population. OFF episodes are a complication of the disease. An estimated one quarter to one half of all people with PD whose symptoms are otherwise managed with ongoing drug therapy experience OFF episodes at least once daily and up to six times daily, with each episode lasting between 30 and 120 minutes.

About Apomorphine

Apomorphine is the only drug approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States, which can be painful and difficult to administer, particularly while suffering an OFF episode.

Cynapsus’ APL-130277 product candidate is a sublingual formulation of apomorphine for the treatment of OFF episodes. If approved, APL‐130277 will provide patients with a convenient and easy alternative to multiple daily injections.

Conference Call and Webcast

Cynapsus management will host an analyst meeting and live webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time. To view the live webcast, visit the Investor Relations section of the Company’s website at www.cynapsus.ca .

A replay of the webcast will be available 2 hours after completion of the meeting, and archived for 90 days on the Company's website at  www.cynapsus.ca in the Investor Relations section.

About Cynapsus

Cynapsus is a specialty CNS pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit an NDA in the first half of 2017. For additional company information, please visit our website www.cynapsus.ca .  For more information about the Phase 3 studies, including enrollment criteria, please visit the website found here http://cth300and301trials.cynapsus.ca/  

Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, the Company’s expectation for filing an NDA in the first half of 2017; expectations regarding the Company’s clinical and regulatory activities, including without limitation, the anticipated timing, completion and results of Phase 3 and other clinical studies; and beliefs related to potential benefits, effectiveness and demand for, the Company’s product candidate. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-Q filed with the United States Securities and Exchange Commission (the “SEC”) on May 11, 2016, and its other filings and reports in the United States with the SEC available on the SEC’s web site at  www.sec.gov , and in Canada with the various Canadian securities regulators, which are available online at  www.sedar.com . Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law. 

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.

Contact Information Company Contact: Kristen Galfetti Vice President, Investor Relations (416) 703-2449 x246 kgalfetti@cynapsus.ca Media Contact: Russo Partners LLC Matt Middleman (212) 845-4272 matt.middleman@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 9

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 76

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 189

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from BioRestorative's CEO on Regenerative Medicine

Updated Category News Views 168

CEO Lance Alstodt Discusses BioRestorative's Vision In a recent interview on “The Big Biz Show,” the dynamic CEO of BioRestorative Therapies, Inc., Lance Alstodt, shared invaluable insights into the company's journey. As a pioneer in regenerative medicine, BioRestorative focuses on innovative stem cell-based therapies aimed at addressing various medical challenges....

Continue Reading
Hargreave Hale AIM VCT PLC NAV Announcement

Updated Category News Views 73

Hargreave Hale AIM VCT PLC (the “Company”) Net Asset Value Announcement As of the close of business on 16 August 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc stands at: NAV per Ordinary share of 1p – 42.03 pence. Contact Information If you need more information, please reach out to: JTC (UK) Limited Uloma Adighibe Alexandria Tivey Email...

Continue Reading
Discover Luxury Living at Toll Brothers' New Community in Texas

Updated Category News Views 150

Introducing Toll Brothers at George's Ranch In a splendid showcase of luxury living, Toll Brothers, Inc. (NYSE:TOL) has unveiled its newest community, Toll Brothers at George's Ranch, located in the serene surroundings of Boerne, Texas. This exciting development marks an important addition to the San Antonio area, where elegance meets modern design. Grand Opening...

Continue Reading
xLean's TR1 Robot Revolutionizes Cleaning Technology

Updated Category News Views 224

xLean's Innovative TR1 Takes Center Stage xLean Robotics concluded an exciting showcase at IFA 2025, where its groundbreaking TR1, the world's first dual-form transformable floor washing robot, earned several prestigious awards. This innovative device was recognized as the 'Best in IFA Next Winner' and 'Best in Design Honoree,' and it was featured as one of the 'Top 5...

Continue Reading
Alpha Modus Sues H&M for Patent Infringement Regarding AI Tech

Updated Category News Views 165

Alpha Modus Files Patent Infringement Lawsuit Against H&M Alpha Modus, Corp. is making headlines for filing a substantial patent infringement lawsuit against H&M Fashion USA, Inc. in the United States District Court for the Eastern District of Texas, Marshall Division. This legal action centers around allegations that H&M's retail operations in the U.S. are infringing...

Continue Reading